At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 421 enrolled
Drug / intervention
Methylprednisolone (MPA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Incidence of Flare Reaction Following Shoulder Steroid Injections: Comparison of Depo-medrol (Methylprednisolone) and Kenalog (Triamcinolone)
In Brief
A Phase 4 clinical trial evaluating Methylprednisolone (MPA) and Triamcinolone Acetonide (TA) for Shoulder Pain. Completed, enrolled 421 participants across 1 site.
Detailed Summary
Compare FLARE reactions (increase in VAS by two or more points) in the first 48 hours following a shoulder injection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShoulder Pain
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedJun 2022
Primary CompletionAug 2022
Study CompletionSep 2022
TodayJul 2026
First PostedJun 29, 2022
Enrollment StartJan 1, 2020
Primary CompletionAug 31, 2022
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.0 years ago
Interventions
Methylprednisolone (MPA)drug
injection into subacromial or glenohumeral space with MPA
Triamcinolone Acetonide (TA)drug
injection into subacromial or glenohumeral space with TA